Antibody Engineering & Therapeutics Asia is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Tomoyuki Igawa, Ph.D., is currently the Chief Executive Officer of Chugai Pharamabody Research in Singapore. He has started working at Chugai Pharmaceutical as Research scientist, and had experiences as project leader for emicizumab and satralizumab. He graduated and awarded PhD from University of Tokyo for studies in Engineering, Chemistry and Biotechnology.
After a couple of year as Research Scientist working on early CMC development and pharmacokinetics, he focused on antibody engineering which lead to the discovery of bispecific antibody HEMLIBRA® (emicizumab) for hemophilia A, recycling antibody and sweeping antibody technology for various applications. Recent years he has been responsible for biologics drug discovery and cancer immunotherapy discovery. As a Global biologics leader, he overseas biological discovery research both in Japan and Singapore. Dr.Igawa likes to work in the area of interface between antibody technology and disease mechanism especially for unmet needs in the world.